marlinpaull

[marlinpaull]

Australia: Get VISUDYNE / Verteporfin Online with Confidence

Explore the suitability of accessing VISUDYNE / Verteporfin online in Australia with confidence. Faith reputable online stores to deliver prescribed products to your doorstep. Enjoy a seamless and safe process, confirming timely and reliable healthcare solutions. Embrace the ease of online prescriptions, making managing your health a hassle-free experience down under.

[marlinpaull]

A Patient Guide to Visudyne (verteporfin for injection) Therapy

Visudyne therapy is a treatment for the wet, or neovascular, form of AMD. It uses a combination of a photoactive drug (a light-activated drug) and light from a non-thermal laser (A laser that does not burn the retina). After administration of Visudyne therapy, your skin and eyes will be photosensitive. As a precaution, avoid direct sunlight and bright lights for five days. Home: • Be sure that if you are near a window in your home during daylight, you have curtains or shades to blockoutdirect sunlight. • Avoid direct sunlight from skylights.

A beneficial aspect of Visudyne therapy is the fact that it can destroy the abnormal blood vessels without causing thermal (heat) damage to the overlying sensory retina. Unlike other AMD treatments, Visudyne therapy may work toward stabilizing vision. In other words, this treatment may confine and inhibit the progression of wet AMD, and thereby preserve patients’ vision. Visudyne may not stop vision loss in all patients. Adverse reactions to Visudyne therapy may include: skin reactions at the injection site, blurred vision, or vision defects. 2.2% of Visudyne patients had back pain related to infusion. Severe vision decrease occurred in 1% to 4% of patients. Your doctor should be consulted if any of these conditions exist after Visudyne treatment.

[marlinpaull]

Ocular photodynamic therapy with Visudyne® (verteporfin) for macular degeneration treatment

Photodynamic therapy with Visudyne (verteporfin) is clinically proven and, therefore, medically necessary when the following criteria are met: · Members present with a diagnosis of neovascular wet age-related macular degeneration — when abnormal blood vessels grow under the retina and macula — with prematurely classic subfoveal choroidal neovascularization lesions, where the area of classic choroidal neovascularization occupies at least 50 percent of the entire lesion at the initial visit, as determined by a fluorescein angiogram. OR · Members present with a subfoveal occult with no classic choroidal neovascularization associated with age-related macular degeneration, when lesions are small (under four disk areas) at initial treatment within three months prior to initial treatment. · Members present with minimally classic choroidal neovascularization where the area of classic choroidal neovascularization occupies Members present with juxtafoveal lesions, as an off-label use. · Members present with lesions that have shown evidence of progression within three months prior to initial treatment, as documented by visual acuity (at least five letters on an eye examination chart), lesion growth at least one disk area, or the appearance of blood associated with the lesions (American Academy of Ophthalmology, 2015; Royal College of Ophthalmologists, 2013).

[marlinpaull]

Clinical Policy: Verteporfin (Visudyne)

The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for verteporfin (Visudyne®).

Visudyne (verteporfin) is a light-activated drug used in photodynamic therapy. Visudyne therapy is a two-stage process requiring administration of both verteporfin for injection and nonthermal red lights. Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclooxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction. Verteporfin appears to somewhat preferentially accumulate in neovasculature, including choroidal neovasculature. However, animal models indicate that the drug is also present in the retina. Therefore, there may be collateral damage to retinal structures following photoactivation including the retinal pigmented epithelium and outer nuclear layer of the retina. The temporary occlusion of CNV following Visudyne therapy has been confirmed in humans by fluorescein angiography.

[marlinpaull]

Visudyne 15 mg powder for solution for infusion

Visudyne should be administered only by ophthalmologists experienced in the management of patients with age-related macular degeneration or with pathological myopia. Posology Adults, including the elderly (≥65 years old) Visudyne photodynamic therapy (PDT) is a two-step process: The first step is a 10-minute intravenous infusion of Visudyne at a dose of 6 mg/m2 body surface area, diluted in 30 ml infusion solution (see section 6.6). The second step is the light activation of Visudyne at 15 minutes after the start of the infusion (see “Method of administration”). Patients should be re-evaluated every 3 months. In the event of recurrent CNV leakage, Visudyne therapy may be given up to 4 times per year. Treatment of the second eye with Visudyne There are no clinical data to support concomitant treatment of the second eye. However, if treatment of the second eye is deemed necessary, light should be applied to the second eye immediately after light application in the first eye but no later than 20 minutes from the start of the infusion.

[marlinpaull]

VERTEPORFIN FOR INJECTION

VISUDYNE® (verteporfin for injection) is a light activated drug used in photodynamic therapy.

The finished drug product is a lyophilized dark green cake. Verteporfin is a 1:1 mixture of two

regioisomers (I and II), represented by the following structures:

VISUDYNE (verteporfin for injection) therapy is a two-stage process requiring administration of

both verteporfin for injection and nonthermal red light.

Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated

by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive

oxygen radicals are generated. Light activation of verteporfin results in local damage to

neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to

release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclooxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin

clot formation and vasoconstriction. Verteporfin appears to somewhat preferentially accumulate

in neovasculature, including choroidal neovasculature. However, animal models indicate that the

drug is also present in the retina. Therefore, there may be collateral damage to retinal structures

following photoactivation including the retinal pigmented epithelium and outer nuclear layer of

the retina. The temporary occlusion of choroidal neovascularization (CNV) following Visudyne therapy has been confirmed in humans by fluorescein angiography